Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice

Fig. 2

Forest plot of real-world progression-free survival by subgroup* after sIPTW. Dx, diagnosis; ECOG PS, Eastern Cooperative Oncology Group performance status; LET, letrozole; ND, not documented; PAL, palbociclib; sIPTW, stabilized inverse probability of treatment weighting. *Race by Cohort interaction was the only subgroup variable-by-treatment cohort interaction that was significant (P=0.0010); however, race data were not known in the “not documented” race group.†Bone-only disease was defined as metastatic disease in the bone only.‡Visceral disease was defined as metastatic disease in the lung and/or liver; patients could have had other sites of metastases. No visceral disease was defined as no lung or liver metastases. The total patient population for different subgroups varied due to the application of sIPTW. Therefore, the total n number for each subgroup may not have always equaled the N number of the treatment arm (due to rounding error and categorization differences)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us